New immunotherapy may avoid bladder removal
The study paragraphs published in The Lancet Oncology journal reveal that a new immunotherapy is being used instead of bladder removal in patients with high-risk bladder cancer, where more than 81% of patients were able to avoid surgery two years after treatment. The therapy showed a complete response in 75% of patients, lasting over two years in about 60% of them, with generally mild side effects. This treatment contributes to preserving quality of life and reducing the need for surgeries, offering promising results in combating this aggressive type of cancer.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)